Skip to main content
Premium Trial:

Request an Annual Quote

Aptalis Pharma taps NuMedii to Select Candidates for Drug Research

Premium

NuMedii said this week that it will use its predictive platform to identify potential therapeutic candidates for gastrointestinal disorders and cystic fibrosis for Aptalis Pharma.

Under the terms of the collaboration, NuMedii will provide proprietary, de-risked drug candidates, while Aptalis will handle the development and commercialization of the treatments it chooses to pursue.

Furthermore, NuMedii will receive an initial upfront payment along with development and commercial milestone payments plus royalties on sales of each product developed under the collaboration, the company said.

NuMedii was spun out of Stanford University last year to commercialize computational methods for identifying new drugs (BI 12/2/2011). The company uses network-based algorithms to analyze disease, pharmacological, and clinical data in order to identify drug-disease connections and biomarkers that are predictive of efficacy.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.